|Bid||266.24 x 1100|
|Ask||266.32 x 800|
|Day's range||260.74 - 267.18|
|52-week range||219.90 - 317.17|
|Beta (5Y monthly)||1.03|
|PE ratio (TTM)||9.45|
|Earnings date||10 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||29 Mar 1994|
|1y target est||342.57|
Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q1 sales.
Despite pandemic-led disruptions, Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments.
Strength in Diagnostics and Breast Health businesses is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.